Bioorthogonal Two-Component Drug Delivery in HER2(+) Breast Cancer Mouse Models

Scientific Reports - United Kingdom
doi 10.1038/srep24298
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Radiation-Guided Drug Delivery to Mouse Models of Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2012English

Antitumor Activity of Phenethyl Isothiocyanate in HER2-positive Breast Cancer Models

BMC Medicine
Medicine
2012English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

Breast Cancer Stem Cells in HER2-negative Breast Cancer Cells Contribute to HER2-mediated Radioresistance and Molecular Subtype Conversion: Clinical Implications for Serum HER2 in Recurrent HER2-negative Breast Cancer

Oncotarget
Oncology
2017English

Genetically Engineered ER -Positive Breast Cancer Mouse Models

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2014English

Molecular Cytogenetics of Mouse Models of Breast Cancer

Breast Disease
MedicineCancer ResearchOncology
2004English

HER2 Expression in NF1 Breast Cancer—Response

Cancer Prevention Research
MedicineCancer ResearchOncology
2019English

Serum HER2 Levels Determined by Two Methods in Patients With Metastatic Breast Cancer

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy